Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
6. |
ECCT/23/05/03 | BrainCapture EEG Validation Usability and efficacy of an affordable, smartphone-connected EEG device to bridge the global gap in epilepsy diagnosis |
Principal Investigator(s) 1. Diraj Sokhi Sokhi Site(s) in Kenya Aga Khan University Hospital Nairobi |
View |
7. |
ECCT/23/03/05 | SKY-06 A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
Principal Investigator(s) 1. Dr Primus Ochieng Site(s) in Kenya 1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
8. |
ECCT/22/06/01 | The INSIGHT cohort A cohort for evaluation of open-label PrEP delivery and PrEP preferences among African women |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI RCTP, LUMUMBA SUBCOUNTY HOSPITAL |
View |
9. |
ECCT/25/02/01 | IMPAACT 2037 Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 |
Principal Investigator(s) 1. Lucy C. Koech Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
View |
10. |
ECCT/22/05/02 | BREATHER Plus A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |